Synthetic retinoid Am80 ameliorates chronic graft-versus-host disease by down-regulating Th1 and Th17

Hisakazu Nishimori, Yoshinobu Maeda, Takanori Teshima, Haruko Sugiyama, Koichiro Kobayashi, Yoshiko Yamasuji, Sachiyo Kadohisa, Hidetaka Uryu, Kengo Takeuchi, Takehiro Tanaka, Tadashi Yoshino, Yoichiro Iwakura, Mitsune Tanimoto

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Chronic GVHD (cGVHD) is a main cause of late death and morbidity after allogeneic hematopoietic cell transplantation, but its pathogenesis remains unclear. We investigated the roles of Th subsets in cGVHD with the use of a well-defined mouse model of cGVHD. In this model, development of cGVHD was associated with up-regulated Th1, Th2, and Th17 responses. Th1 and Th2 responses were up-regulated early after BM transplantation, followed by a subsequent up-regulation of Th17 cells. Significantly greater numbers of Th17 cells were infiltrated in the lung and liver from allogeneic recipients than those from syngeneic recipients. We then evaluated the roles of Th1 and Th17 in cGVHD with the use of IFN-γ-deficient and IL-17-deficient mice as donors. Infusion of IFN-γ -/- or IL-17 -/- T cells attenuated cGVHD in the skin and salivary glands. Am80, a potent synthetic retinoid, regulated both Th1 and Th17 responses as well as TGF-β expression in the skin, resulting in an attenuation of cutaneous cGVHD. These results suggest that Th1 and Th17 contribute to the development of cGVHD and that targeting Th1 and Th17 may therefore represent a promising therapeutic strategy for preventing and treating cGVHD.

Original languageEnglish
Pages (from-to)285-295
Number of pages11
JournalBlood
Volume119
Issue number1
DOIs
Publication statusPublished - Jan 5 2012

Fingerprint

Interleukin-17
Retinoids
Graft vs Host Disease
Grafts
Th17 Cells
Skin
T-cells
Liver
Cell Transplantation
Salivary Glands
Cause of Death
Up-Regulation
Transplantation
Morbidity
T-Lymphocytes
Lung
tamibarotene
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Synthetic retinoid Am80 ameliorates chronic graft-versus-host disease by down-regulating Th1 and Th17. / Nishimori, Hisakazu; Maeda, Yoshinobu; Teshima, Takanori; Sugiyama, Haruko; Kobayashi, Koichiro; Yamasuji, Yoshiko; Kadohisa, Sachiyo; Uryu, Hidetaka; Takeuchi, Kengo; Tanaka, Takehiro; Yoshino, Tadashi; Iwakura, Yoichiro; Tanimoto, Mitsune.

In: Blood, Vol. 119, No. 1, 05.01.2012, p. 285-295.

Research output: Contribution to journalArticle

Nishimori, H, Maeda, Y, Teshima, T, Sugiyama, H, Kobayashi, K, Yamasuji, Y, Kadohisa, S, Uryu, H, Takeuchi, K, Tanaka, T, Yoshino, T, Iwakura, Y & Tanimoto, M 2012, 'Synthetic retinoid Am80 ameliorates chronic graft-versus-host disease by down-regulating Th1 and Th17', Blood, vol. 119, no. 1, pp. 285-295. https://doi.org/10.1182/blood-2011-01-332478
Nishimori, Hisakazu ; Maeda, Yoshinobu ; Teshima, Takanori ; Sugiyama, Haruko ; Kobayashi, Koichiro ; Yamasuji, Yoshiko ; Kadohisa, Sachiyo ; Uryu, Hidetaka ; Takeuchi, Kengo ; Tanaka, Takehiro ; Yoshino, Tadashi ; Iwakura, Yoichiro ; Tanimoto, Mitsune. / Synthetic retinoid Am80 ameliorates chronic graft-versus-host disease by down-regulating Th1 and Th17. In: Blood. 2012 ; Vol. 119, No. 1. pp. 285-295.
@article{9ec6478dcb0e4466951194a334968063,
title = "Synthetic retinoid Am80 ameliorates chronic graft-versus-host disease by down-regulating Th1 and Th17",
abstract = "Chronic GVHD (cGVHD) is a main cause of late death and morbidity after allogeneic hematopoietic cell transplantation, but its pathogenesis remains unclear. We investigated the roles of Th subsets in cGVHD with the use of a well-defined mouse model of cGVHD. In this model, development of cGVHD was associated with up-regulated Th1, Th2, and Th17 responses. Th1 and Th2 responses were up-regulated early after BM transplantation, followed by a subsequent up-regulation of Th17 cells. Significantly greater numbers of Th17 cells were infiltrated in the lung and liver from allogeneic recipients than those from syngeneic recipients. We then evaluated the roles of Th1 and Th17 in cGVHD with the use of IFN-γ-deficient and IL-17-deficient mice as donors. Infusion of IFN-γ -/- or IL-17 -/- T cells attenuated cGVHD in the skin and salivary glands. Am80, a potent synthetic retinoid, regulated both Th1 and Th17 responses as well as TGF-β expression in the skin, resulting in an attenuation of cutaneous cGVHD. These results suggest that Th1 and Th17 contribute to the development of cGVHD and that targeting Th1 and Th17 may therefore represent a promising therapeutic strategy for preventing and treating cGVHD.",
author = "Hisakazu Nishimori and Yoshinobu Maeda and Takanori Teshima and Haruko Sugiyama and Koichiro Kobayashi and Yoshiko Yamasuji and Sachiyo Kadohisa and Hidetaka Uryu and Kengo Takeuchi and Takehiro Tanaka and Tadashi Yoshino and Yoichiro Iwakura and Mitsune Tanimoto",
year = "2012",
month = "1",
day = "5",
doi = "10.1182/blood-2011-01-332478",
language = "English",
volume = "119",
pages = "285--295",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - Synthetic retinoid Am80 ameliorates chronic graft-versus-host disease by down-regulating Th1 and Th17

AU - Nishimori, Hisakazu

AU - Maeda, Yoshinobu

AU - Teshima, Takanori

AU - Sugiyama, Haruko

AU - Kobayashi, Koichiro

AU - Yamasuji, Yoshiko

AU - Kadohisa, Sachiyo

AU - Uryu, Hidetaka

AU - Takeuchi, Kengo

AU - Tanaka, Takehiro

AU - Yoshino, Tadashi

AU - Iwakura, Yoichiro

AU - Tanimoto, Mitsune

PY - 2012/1/5

Y1 - 2012/1/5

N2 - Chronic GVHD (cGVHD) is a main cause of late death and morbidity after allogeneic hematopoietic cell transplantation, but its pathogenesis remains unclear. We investigated the roles of Th subsets in cGVHD with the use of a well-defined mouse model of cGVHD. In this model, development of cGVHD was associated with up-regulated Th1, Th2, and Th17 responses. Th1 and Th2 responses were up-regulated early after BM transplantation, followed by a subsequent up-regulation of Th17 cells. Significantly greater numbers of Th17 cells were infiltrated in the lung and liver from allogeneic recipients than those from syngeneic recipients. We then evaluated the roles of Th1 and Th17 in cGVHD with the use of IFN-γ-deficient and IL-17-deficient mice as donors. Infusion of IFN-γ -/- or IL-17 -/- T cells attenuated cGVHD in the skin and salivary glands. Am80, a potent synthetic retinoid, regulated both Th1 and Th17 responses as well as TGF-β expression in the skin, resulting in an attenuation of cutaneous cGVHD. These results suggest that Th1 and Th17 contribute to the development of cGVHD and that targeting Th1 and Th17 may therefore represent a promising therapeutic strategy for preventing and treating cGVHD.

AB - Chronic GVHD (cGVHD) is a main cause of late death and morbidity after allogeneic hematopoietic cell transplantation, but its pathogenesis remains unclear. We investigated the roles of Th subsets in cGVHD with the use of a well-defined mouse model of cGVHD. In this model, development of cGVHD was associated with up-regulated Th1, Th2, and Th17 responses. Th1 and Th2 responses were up-regulated early after BM transplantation, followed by a subsequent up-regulation of Th17 cells. Significantly greater numbers of Th17 cells were infiltrated in the lung and liver from allogeneic recipients than those from syngeneic recipients. We then evaluated the roles of Th1 and Th17 in cGVHD with the use of IFN-γ-deficient and IL-17-deficient mice as donors. Infusion of IFN-γ -/- or IL-17 -/- T cells attenuated cGVHD in the skin and salivary glands. Am80, a potent synthetic retinoid, regulated both Th1 and Th17 responses as well as TGF-β expression in the skin, resulting in an attenuation of cutaneous cGVHD. These results suggest that Th1 and Th17 contribute to the development of cGVHD and that targeting Th1 and Th17 may therefore represent a promising therapeutic strategy for preventing and treating cGVHD.

UR - http://www.scopus.com/inward/record.url?scp=84862908181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862908181&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-01-332478

DO - 10.1182/blood-2011-01-332478

M3 - Article

VL - 119

SP - 285

EP - 295

JO - Blood

JF - Blood

SN - 0006-4971

IS - 1

ER -